Effective half-life of 131I in thyroid cancer patients.

摘要: The oral administration of radioactive 131I is a standard treatment for thyroid carcinoma. One consideration this therapy assuring that other people do not receive significant radiation exposure. In particular, federal and state regulatory authorities stipulate no individual should more than 5 mSv (500 mrem) effective dose-equivalent from the released patient. Patients receiving 1.11 GBq (30 mCi) were traditionally confined as in-patients by regulation until their burdens radioactivity fell below level or external dose rates less 50 microSv (5 per hour at 1 m. Recent guidance recommends use biological elimination well physical decay in calculating confinement time to keep members public mSv. Analysis database 250 administrations cancer shows median half-life least 14 h, with substantial variation. Thus, discharge criteria safety purposes be calculated on basis measurements. release these patients always prompt indicates. results also challenge some long-used assumptions regarding iodine excretion patient population.